查詢結果分析
相關文獻
- Hepatitis B Virus Reactivation After 23 Months of Rituximab-based Chemotherapy in an HBsAg-negative, Anti-HBs-positive Patient With Follicular Lymphoma
- Radiation Therapy in Primary Central Nervous System Lymphoma
- Angiotropic Lymphoma Manifesting as a Solitary Adrenal Tumor in a Case of Ankylosing Spondylitis
- Diagnostic Pitfalls of Fine-Needle Aspiration Cytology and Prognostic Impact of Chemotherapy in Thyroid Lymphoma
- Treatment Results of the TPOG-NHL92 Protocols for Childhood Non-Hodgkin's Lymphomas in Taiwan: A Report from the Taiwan Pediatric Oncology Group (TPOG)
- High Dose Chemotherapy with Peripheral Blood Stem Cells Transplantation in Patients with Relapsed or Refractory Lymphomas-Preliminary Reports
- Clinical Characteristics of and Response to Combination Chemotherapy and Subsequent Application of International Prognostic Index in Non-Hodgkin's Lymphoma--an Experience from a Medical Center in Southern Taiwan
- Enteropathy-associated T-Cell Lymphoma of the Jejunum Complicated with Intestinal Perforation
- 化學治療後口腔潰瘍及感染於惡性淋巴瘤預後之影響--小球性淋巴瘤併有單株副蛋白血症之病例報告
- Differential Response to Chemotherapy in Peripheral T-Cell Lymphoma and Diffuse B-Cell Lymphoma--Features Useful in Treatment Planning
頁籤選單縮合
題 名 | Hepatitis B Virus Reactivation After 23 Months of Rituximab-based Chemotherapy in an HBsAg-negative, Anti-HBs-positive Patient With Follicular Lymphoma=B型肝炎表面抗原陰性,核心抗原陽性之濾泡型淋巴瘤病患接受Rituximab化學治療二十三個月後發生B型肝炎病毒復發 |
---|---|
作 者 | 李懿宬; 黃怡翔; 朱啟仁; 李培正; 林漢傑; 李壽東; | 書刊名 | Journal of the Chinese Medical Association |
卷 期 | 73:3 2010.03[民99.03] |
頁 次 | 頁156-160+CA26 |
分類號 | 415.415 |
關鍵詞 | 核心抗體陽性; 化學治療; B型肝炎復發; 淋巴瘤; Rituximab; Anti-HBc positive; Chemotherapy; HBV reactivation; Non-Hodgkin’s lymphoma; |
語 文 | 英文(English) |
英文摘要 | A 72-year-old female negative for hepatitis B surface antigen (HBsAg) and positive for antibody to hepatitis B surface antigen (anti-HBs) was diagnosed to have follicular lymphoma in 2006. Seventeen cycles of rituximab-based chemotherapy were administered over 23 months. Twelve days after the last cycle of chemotherapy, serum aminotransferase levels were elevated, and hepatitis serology tests revealed reappearance of HBsAg and hepatitis B e antigen (HBeAg), loss of anti-HBs, and positivity for hepatitis B virus (HBV) DNA. Antiviral treatment with entecavir was administered immediately, and the hepatitis flare was controlled. Rituximab-based chemotherapy can induce HBV reactivation even in HBsAg-negative, anti-HBs-positive patients. Early recognition and prompt antiviral treatment is crucial for patients with HBV reactivation during anticancer therapy. |
本系統中英文摘要資訊取自各篇刊載內容。